Clinical Trials Logo

Morphea clinical trials

View clinical trials related to Morphea.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT04922736 Enrolling by invitation - Clinical trials for Graft Vs Host Disease

Patient Reported Outcomes With UVA-1 Therapy for Treatment of Sclerosing Skin Diseases

Start date: June 7, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the degree of improvement seen patient reported outcomes after 30 sessions of UVA-1 therapy in treating systemic scleroderma, morphea, and sclerodermatous Graft-Versus-Host Disease. While patients have verbally reported improvement of their sclerosing skin disease with UVA-1, patient reported outcomes have not been rigorously studied. In sclerosing skin diseases where clinical change is difficult to measure, patient reported outcomes may offer a better way to study the impact of treatments like UVA-1. This will be a non-blinded, non-randomized prospective trial using UVA-1 phototherapy in patients with established sclerosing skin disease. Patients will report the severity of their condition using multiple patient reported outcomes and will also be analyzed using multiple clinical investigator assessments at the beginning and end of 30 treatment sessions.